On July 29, 2026, the Nasdaq Hearings Panel granted Genprex an exception to maintain its listing on The Nasdaq Capital Market despite failing to meet the $1.00 Minimum Bid Price requirement. The company must demonstrate compliance by July 29, 2026, and maintain a closing bid price at or above $1.00 for each trading day until December 7, 2026. Genprex implemented a one-for-twenty-two (1:22) reverse stock split effective July 16, 2026, to address the deficiency. Failure to comply with these terms may result in delisting, which could negatively impact liquidity and capital access. Genprex is a clinical-stage biopharmaceutical company developing targeted therapies for cancer.

Genprex, Inc. announced a one-for-twenty-two (1:22) reverse stock split of its common stock, effective July 16, 2026, to help regain compliance with Nasdaq's $1.00 minimum bid price requirement. The company also provided updates on its Acclaim-1 and Acclaim-3 clinical trials for its gene therapy programs. Genprex, Inc. is a biotechnology company focused on oncology and diabetes gene therapy.

Genprex, Inc. announced that the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering the use of Reqorsa® Gene Therapy (quaratusugene ozeplasmid) in combination with PD-1 or PD-L1 antibodies for treating lung cancer. This patent expands on existing patents granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore, Europe, and other regions. Genprex, Inc. is a biotechnology company developing gene therapy products for oncology and diabetes.

At its 2026 Annual Meeting on June 18, 2026, Genprex, Inc. stockholders approved an amended and restated 2018 Equity Incentive Plan, increasing authorized common stock issuance by 1,850,000 shares. Stockholders also approved an amendment to the Certificate of Incorporation granting the Board of Directors sole discretion to implement a reverse stock split between 1:5 and 1:50 at any time before December 31, 2027. Other approved items included the election of directors Jose Antonio Moreno Toscano and Ryan M. Confer, and the ratification of WithumSmith+Brown, PC as the independent auditor. Genprex is a biotechnology company that develops therapeutic products.

Genprex, Inc. received a notification from Nasdaq indicating that its common stock is in violation of the $1.00 minimum bid price requirement. Because the company executed a reverse stock split on October 21, 2025, it is ineligible for a 180-day compliance period. The company intends to request a hearing before a Nasdaq Hearings Panel to stay any delisting action. Management is considering further actions, including another reverse stock split, to regain compliance. Genprex, Inc. is a biotechnology company focused on gene therapy.